Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma

Fenk, Roland; Haas, Rainer; Kronenwett, Ralf

doi:10.1080/10245330310001638965

Cited by 14 publications

(16 citation statements)

References 162 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All raw data are shown in a Supplementary Table E2 (online only, available at www.exphem.org). The ASO-PCR is powerful and sensitive for detecting MRD [4,[7][8][9][13][14][15][16][17], but it has some limitations. One problem is the cost of designing patient-specific ASO primers.…”

Section: Discussionmentioning

confidence: 99%

Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients

Sata

Shibayama

Maeda

et al. 2015

Experimental Hematology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients

Sata

Shibayama

Maeda

et al. 2015

Experimental Hematology

View full text Add to dashboard Cite

“…20 ). Since these probes can be used for several patients, there was a significant reduction in the price of this method compared to methods using patient-specific probes 17,32 .…”

Section: Discussionmentioning

confidence: 99%

“…The rate of ASO RQ-PCR is considerably variable because of significant heterogeneity of MM cells but approximately ranging from 30% to over 80% (ref. 22,23,32,33 ). In the remaining 3 oligoclonal patients, we were not able to perform the quantification because of the oligoclonal nature of the disease.…”

Section: Discussionmentioning

confidence: 99%

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Sedlaříková¹,

Kubiczkova²,

Kryukov³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

Aims. Multiple myeloma (MM), the second most common hematological cancer, is a lymphoproliferative disease of terminally differentiated B lymphocytes characterized by expansion of monoclonal plasma cells. With the introduction of new drugs, MM has become a hard-to-treat disease. The aim of treatment is clinical remission and eradication of clinical manifestations but most MM patients eventually relapse. For this reason, more accurate monitoring of remission and relapse using molecular biology techniques is at the center of attention. Methods. For monitoring, we used allele-specific PCR and quantitative real-time PCR based on specific detection of VDJ immunoglobulin heavy chain gene rearrangement of clonal cells for monitoring. The hypervariable region of IgH rearrangement is used for detection of minimal residual disease (MRD) in MM as this sequence is used for allele-specific primers and probe design. This technique is a complementary tool for flow cytometry in MRD detection; however, it has not been established in the Czech Republic so far.Results. Qualitative and quantitative MRD detection was performed in 50% (5/10) patients and qualitative MRD detection in another 3 oligoclonal patients. Conclusions. Next to flow cytometry, detection of MRD by qPCR is a viable option and has been introduced in the Czech Republic.

show abstract

“…However, being highly specific for the disease clone, they are not universally applicable to all patients as clone-specific primers must be designed (see Chap. 4) [24,[31][32][33].…”

Section: Monitoring After Treatmentmentioning

confidence: 99%

Plasma Cell Myeloma and Other Plasma Cell Dyscrasias

Yared

2009

Neoplastic Hematopathology

View full text Add to dashboard Cite

Overview of Plasma Cell NeoplasmsPlasma cell neoplasms encompass a group of diseases with varying clinical manifestations but with at least one common feature, the production by neoplastic plasma cells with a monoclonal immunoglobulin protein (M-protein, or paraprotein). These diseases include plasma cell myeloma (PCM) (and its clinical variants), solitary plasmacytoma of bone, extraosseous plasmacytoma, and the monoclonal immunoglobulin deposition diseases (primary amyloidosis and monoclonal light and heavy chain deposition diseases) (Fig. 19-1). The clinical variants of PCM now recognized by the World Health Organization (WHO) are symptomatic PCM, asymptomatic PCM (also known as smoldering PCM), nonsecretory myeloma, and plasma cell leukemia (PCL).PCM will be the primary focus of this chapter, but other plasma cell neoplasms enter into the differential diagnosis. Solitary plasmacytoma of bone lacks evidence of systemic dissemination or diagnostic features of PCM, but can undergo progression to myeloma. Extraosseous plasmacytoma is restricted to extramedullary tissues, most frequently the upper respiratory tract, usually only produces symptoms related to its mass effect, and rarely progresses to PCM. Primary amyloidosis is the deposition of immunoglobulin light chain aggregates that show apple-green birefringence on a Congo red stain (i.e., AL amyloid) and usually sparse clonal plasma cell proliferations. Clinical manifestations of the effects of amyloid on producing organ or tissue dysfunction include nephrotic syndrome, heart failure, malabsorption, peripheral neuropathy, and bleeding disorders. The related light and heavy chain deposition diseases are due to deposition of non-birefrigent immunoglobulin and produce a similar range of effects although their ultrastructural appearance is different than amyloid. These include the immunoglobulin "heavy chain deposition" disorders which

show abstract

Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma

Cited by 14 publications

References 162 publications

Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients

Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Plasma Cell Myeloma and Other Plasma Cell Dyscrasias

Contact Info

Product

Resources

About